Relapsed/Refractory HER2+ Metastatic Breast Cancer

The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.

Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.

The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.

The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.

The experts present and discuss a case of a patient with relapsed HER2+ metastatic breast cancer with stable brain metastases.

The experts discuss data from clinical trials of metastatic breast cancer with brain involvement.

Key opinion leaders consider later-lines of therapy in metastatic breast cancer with lung and brain involvement.

A panel of experts review the tucatinib regimen including adverse effects to keep an eye on.

Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.

Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.

The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.